Immutep Signs Licensing Agreement with Dr. Reddy's for Efti Commercialisation Outside North America, Europe, and Japan
I'm PortAI, I can summarize articles.
Immutep Limited has signed a strategic collaboration and exclusive licensing agreement with Dr. Reddy’s Laboratories for Eftilagimod Alfa (efti) outside North America, Europe, Japan, and Greater China. Immutep will receive USD 20 million upfront and potential milestone payments up to USD 349.5 million, plus royalties. Dr. Reddy’s gains exclusive rights in specified territories, while Immutep retains rights in North America, Europe, Japan, and Greater China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments